Next-Gen Vaccines for Developing Nations Tailoring Vaccine Development
0
+
Senior Attendees
Senior professionals across development, manufacturing, distribution, regulatory affairs, and strategic partnerships in both the vaccine and biologics sectors will attend, focusing on advancing global immunization and accelerating biologics development in India.
0
+
Expert Speakers
C-suite executives, leading scientists, industry experts, and policymakers sharing insights on biologics and vaccine innovation, global collaboration, and solutions to enhance access and equity.
0
+
Companies Represented
Representing vaccine and biologics developers, manufacturers, solution providers, regulatory bodies, global health organizations, and research institutions driving progress across the biopharma ecosystem.
Day 1 | 17 March 2027 |
Day 2 | 18 March 2027 |
|||
|
|
|
|
|
|
Leadership Session
India’s Biologics & Vaccine Landscape - Market Trends, Public Health Priorities & Global Opportunities
|
Advancing Vaccine R&D, Regulation & Commercialisation
|
Opening Keynote:
What's Next for India Biologics Landscape? Emerging Technologies and Industry Transformation |
Breakthroughs in Vaccine Technologies
The Role of mRNA Platforms
|
|
| Morning Tea Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | ||||
|
Manufacturing Automation, Digitalization, and Bioprocessing 4.0:
AI and Digital Twins
|
Next-Generation Vaccine Platforms & Innovation
|
Downstream Processing & Purification Excellence:
Advancing Process Intensification, Product Quality, Yield & Manufacturing Performance
|
Scaling Up Vaccine Manufacturing:
From Drug Substance to Aseptic Fill-Finish & Advanced Packaging
|
|
| Lunch Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | ||||
|
Advancing from Research & Formulation to Clinical Trials
|
Preventive Vaccines: Advancements in Disease Prevention and Immunization Strategies
|
Regulatory, Scientific, and Commercial Frameworks
|
Vaccine Supply Chain & Distribution Strategy
|
|
| Afternoon Tea Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | ||||
|
Tech Transfer, Scale-Up & CMC Excellence:
Bridging Development and Commercialization
|
Development of Vaccines for Emerging Diseases
Accelerating Vaccine Research for New Threats
|
Building India's Next-Generation Biologics Ecosystem Accelerating
Accelerating Collaboration, Innovation & Commercial Success |
||
| End of Conference Day 1 | ||||
| Biopharma Excellence Awards 2027 | ||||
Day 1 | 17 March 2027 | |
|
|
|
|
Leadership Session
India’s Biologics & Vaccine Landscape - Market Trends, Public Health Priorities & Global Opportunities
|
Advancing Vaccine R&D, Regulation & Commercialisation
|
| Morning Tea Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Manufacturing Automation, Digitalization, and Bioprocessing 4.0:
AI and Digital Twins
|
Next-Generation Vaccine Platforms & Innovation
|
| Lunch Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Advancing from Research & Formulation to Clinical Trials
|
Preventive Vaccines: Advancements in Disease Prevention and Immunization Strategies
|
| Afternoon Tea Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Tech Transfer, Scale-Up & CMC Excellence:
Bridging Development and Commercialization
|
Development of Vaccines for Emerging Diseases
Accelerating Vaccine Research for New Threats
|
| End of Conference Day 1 | |
| Biopharma Excellence Awards 2027 | |
Day 2 | 18 March 2027 | |
|
|
|
|
Opening Keynote:
What's Next for India Biologics Landscape? Emerging Technologies and Industry Transformation |
Breakthroughs in Vaccine Technologies
The Role of mRNA Platforms
|
| Morning Tea Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Downstream Processing & Purification Excellence:
Advancing Process Intensification, Product Quality, Yield & Manufacturing Performance
|
Scaling Up Vaccine Manufacturing:
From Drug Substance to Aseptic Fill-Finish & Advanced Packaging
|
| Lunch Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Regulatory, Scientific, and Commercial Frameworks
|
Vaccine Supply Chain & Distribution Strategy
|
| Afternoon Tea Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Building India's Next-Generation Biologics Ecosystem Accelerating
Accelerating Collaboration, Innovation & Commercial Success |
|
| End of Conference | |
DAY 1
17 March 2027
08:55
Chairman’s Opening Address
09:00
Leadership Panel
From Vaccine Manufacturing Powerhouse to Global Innovation Hub – What’s Next for South Asia?
- Building on South Asia’s established strength in global vaccine manufacturing. Moving from high-volume production towards next-generation vaccine innovation.
- Scaling regional capabilities from R&D and clinical development to commercialisation.
- Strengthening supply chains, technology and manufacturing infrastructure.
- Creating stronger industry, government and research partnerships to drive the next phase of growth.
Panellists
Dr. Kapil Maithal
President – Vaccines & Diagnostics, Zydus Lifesciences Limited, India
09:50
Advancing Vaccine Development Through Integrated R&D and Process Innovation
- Accelerating vaccine R&D through advanced analytical and process development technologies.
- Improving development timelines, product quality, and scalability from research to commercialisation.
- Leveraging AI, automation, single-use technologies, and advanced analytics in vaccine development.
- Strengthening collaboration to overcome technical and development bottlenecks.
- Enabling faster and more scalable pathways from vaccine discovery to manufacturing.
Solution Provider
Reserved for Solution Provider
10:05
Navigating Vaccine Regulatory Pathways: FDA Perspectives on R&D, Innovation & Commercialization
- Regulatory considerations across vaccine R&D and development.
- Using advanced analytics and modern technologies to support regulatory submissions.
- Regulatory pathways for scaling vaccines from development to commercialisation.
- Building regulatory confidence in new vaccine technologies and manufacturing approaches.
- Engaging with the FDA early to accelerate development and regulatory decision-making.
11:00
Advancing Protein-Based Vaccine Platforms: From Antigen Engineering to Preclinical Validation
- Advancing antigen engineering and protein design to improve vaccine stability, immunogenicity and protective efficacy.
- Optimising recombinant protein vaccine platforms through antigen stabilisation and advanced expression strategies.
- Strengthening preclinical validation through immunogenicity, safety and efficacy assessment of novel vaccine candidates.
- Translating promising candidates from preclinical research toward clinical development and scalable manufacturing.
Dr. Chakshusmathi Ghadiyaram
Head – Pre-Clinical R&D, Mynvax, India
11:25
Supporting the Commercialization of Next-Generation Vaccines Through Integrated Manufacturing and Process Innovation
- Scaling manufacturing for emerging vaccine modalities with flexible and platform-based production.
- Enhancing process development, technology transfer, and quality systems for efficient commercialization.
- Building resilient manufacturing infrastructure to strengthen global vaccine supply and pandemic preparedness.
Solution Provider
Reserved for Solution Provider
11:40
Advancing Next-Generation Vaccine Delivery Systems for Improved Protection and Accessibility
- Exploring innovative delivery technologies, including needle-free, intranasal, oral, and microneedle-based vaccines.
- Improving vaccine stability, patient acceptance, and immunization coverage through novel delivery approaches.
- Accelerating the translation of innovative delivery technologies into clinical practice.
12:05
Unlocking the Potential of Novel Adjuvants and Immunoengineering in Next-Generation Vaccines
- Enhancing vaccine efficacy through innovative adjuvant technologies.
- Improving immune responses for challenging infectious diseases.
- Accelerating the development of durable and broad-spectrum vaccine protection.
02:00
Expanding India's Immunization Strategy: Protecting Beyond Childhood Vaccination
- Expanding immunization programmes across adolescents, adults, pregnant women, and high-risk populations.
- Leveraging real-world evidence and disease surveillance to guide vaccination policies.
- Enhancing public awareness, equitable access, and vaccine confidence to improve coverage.
02:30
Transforming Immunization Programmes Through Digital Health, Data & Vaccine Intelligence
- Using digital technologies to improve immunization planning, coverage, and programme performance.
- Leveraging data analytics and disease surveillance to support evidence-based vaccination strategies.
- Enhancing collaboration across healthcare systems to strengthen preventive immunization outcomes.
Dr. Santosh Taur
Director Medical Affairs, Vaccines & Digital, Pfizer Ltd., India
02:45
Advancing Dengue Prevention: Next-Generation Vaccines, Surveillance & Immunization Strategies
- Addressing the growing dengue burden through next-generation vaccination strategies and integrated public health approaches.
- The evolving role of dengue vaccines alongside surveillance, vector control, and outbreak preparedness.
- Accelerating equitable access, policy adoption, and implementation of dengue immunization programmes in endemic regions.
03:10
Strengthening India's Disease Prevention Strategy Through Preventive Vaccination
- Addressing India's evolving infectious disease landscape through vaccination.
- Enhancing collaboration between government, industry, and public health stakeholders.
- Expanding access to preventive vaccines to improve population health outcomes.
04:05
Preparing for Disease X: Accelerating Vaccine Development for Emerging Infectious Threats
- Strengthening India's preparedness for emerging and re-emerging infectious diseases.
- Advancing collaborative R&D, surveillance, and rapid-response vaccine development.
- Enhancing partnerships across government, academia, industry, and global health organizations to improve outbreak preparedness.
04:30
Accelerating Vaccine Research for Emerging Diseases Through AI, Genomics & Advanced Research Technologies
- Leveraging AI, genomics, and bioinformatics to accelerate vaccine discovery.
- Supporting rapid antigen identification and translational vaccine research.
- Enabling collaborative research ecosystems to shorten vaccine development timelines
Solution Provider
Reserved for Solution Provider
04:45
Enabling Rapid Vaccine Development for Emerging Diseases Through Flexible Manufacturing & Platform Technologies
- Accelerating scale-up using platform technologies and flexible manufacturing.
- Supporting rapid technology transfer and process development for outbreak response.
- Building resilient manufacturing capabilities to strengthen pandemic preparedness.
DAY 2
18 March 2027
08:55
Chairman’s Opening Address
09:00
Panel Discussion
The Future of Vaccine Innovation – Are Next-Generation Technologies Ready to Transform Global Immunization?
- Evaluating the readiness of mRNA, saRNA, circular RNA, viral vector, and protein-based vaccine platforms.
- Overcoming scientific, regulatory, and manufacturing challenges for widespread adoption.
- Building collaborations to accelerate the translation of breakthrough technologies into public health impact.
Panellists
Dr. Vaibhav Salvi
Director and Head – Clinical Study Unit, India and South East Asia, Sanofi, India
Dr. Prem Singh
Director & Senior Technical Advisor, Immunization, Jhpiego, India
09:50
Accelerating Next-Generation Vaccine Development Through Advanced R&D & Manufacturing Technologies
- Advancing process development, analytical technologies and scalable manufacturing for emerging vaccine platforms.
- Addressing challenges in scale-up, quality, stability and technology transfer.
- Leveraging AI, automation, digitalisation and advanced processing technologies to improve development efficiency.
- Enabling faster transition from vaccine discovery and clinical development to commercial manufacturing.
Solution Provider
Reserved for Solution Provider
10:05
Unlocking the Full Potential of mRNA Platforms: From Pandemic Response to Broad-Spectrum Disease Prevention
- Expanding mRNA applications beyond COVID-19 into infectious diseases and therapeutic vaccines.
- Addressing manufacturing, stability, and delivery challenges for mRNA vaccines.
- Accelerating global collaboration to advance mRNA innovation and commercialization
11:00
From Pilot to Commercial Scale: Overcoming the Challenges of Vaccine Manufacturing Scale-Up
- Scaling processes while maintaining product quality and consistency
- Technology transfer and process validation
- Manufacturing capacity planning and facility readiness
- Managing yield, throughput and batch-to-batch variability
- Building flexible and future-ready vaccine manufacturing capacity
11:25
Enabling Scalable Vaccine Manufacturing: Technologies for High-Throughput Fill-Finish & Packaging
- Advanced filling and packaging technologies
- Automation and robotics for high-throughput operations
- Integrated inspection, serialization and packaging solutions
- Digitalisation of fill-finish and packaging lines
- Flexible technologies for multi-product vaccine facilities Supporting manufacturers through scale-up, tech transfer and facility modernisation
Solution Provider
Reserved for Solution Provider
11:40
Aseptic Fill-Finish Excellence: Strengthening Sterility Assurance & Contamination Control
- Optimising aseptic filling operations for vaccines
- Contamination Control Strategy (CCS) and environmental monitoring
- Sterility assurance across filling operations
- Reducing human intervention and contamination risks Isolators, RABS and closed-system approaches
- Maintaining GMP compliance during scale-up
12:05
Next-Generation Vaccine Packaging: Improving Container Closure, Product Protection & Manufacturing Efficiency
- Selecting the right vial, syringe and container- closure systems
- Container Closure Integrity (CCI) and stability considerations
- Packaging challenges for temperature-sensitive vaccines
- Improving packaging-line efficiency and automation
- Reducing material waste and improving sustainability
- Preparing packaging formats for large-scale immunisation programmes
02:00
Fireside Chat
Building Resilient Vaccine Supply Chains in an Era of Global Uncertainty
- Lessons learned from recent global supply chain disruptions.
- Balancing local manufacturing with global distribution networks.
- Preparing supply chains for future public health emergencies.
02:30
Transforming Vaccine Supply Chains Through Digitalization, AI & End-to-End Visibility
- Using AI, IoT, and digital platforms to improve supply chain planning and execution.
- Enhancing traceability, inventory optimization, and predictive decision-making.
- Building connected supply chain ecosystems to improve operational efficiency.
Solution Provider
Reserved for Solution Provider
02:45
Improving Vaccine Access Through Innovative Distribution Models and Public–Private Collaboration
- Strengthening last-mile delivery in urban, rural, and underserved communities.
- Building partnerships to improve equitable vaccine access and distribution.
- Addressing infrastructure and operational challenges across diverse healthcare settings.
03:10
Future-Proofing Vaccine Supply Networks Through Risk Management and Strategic Partnerships
- Managing supply chain disruptions through proactive risk mitigation.
- Diversifying sourcing and strengthening regional manufacturing networks.
- Building agile supply chains to support future pandemic preparedness.
04:05
Strategic Outlook Panel
Enabling a Collaborative Biologics Ecosystem for Sustainable Growth and Global Impact
- Cross-sector collaboration driving the next wave of biologics innovation
- CDMO, biotech and pharma partnerships deepening across the ecosystem
- Talent development building the industry’s future leadership pipeline
- Digital culture accelerating innovation and collaboration across teams
04:40
Beyond Biosimilars: Building India’s Next Generation of Innovative Biologics
- Expanding pipelines beyond traditional biosimilar development
- Advancing novel antibodies and emerging biologic modalities
- Strengthening translational capabilities for homegrown biologics innovation
- Converting scientific assets into globally competitive products
DAY 1
17 March 2027
08:55
Chairman’s Opening Address
09:00
Leadership Panel
Unlocking the Next Chapter of India's Biologics Industry - Investment & Strategic Growth
- Key forces shaping the evolution of India’s biologics industry.
- Investment priorities strengthening industry capacity and capabilities.
- Balancing domestic growth with international market ambitions.
- Addressing capability gaps across the biologics value chain.
- Strengthening India’s position within the global biologics industry.
09:50
Building Biologics Capability at Scale: Technologies Enabling Faster Development & Operational Agility
- Connecting development technologies across the biologics lifecycle.
- Improving scalability without adding unnecessary process complexity.
- Reducing development bottlenecks through integrated technology platforms.
- Enabling flexible capabilities across diverse biologics portfolios.
- Supporting faster progression towards clinical and commercial readiness.
Solution Provider
Reserved for Solution Provider
10:05
FDA Perspective: Translating Scientific Innovation into Regulatory-Ready Biologics Development
- Building regulatory strategy alongside early product development.
- Demonstrating product understanding through robust scientific evidence.
- Aligning development decisions with evolving regulatory expectations.
- Strengthening regulatory readiness before pivotal development milestones.
11:00
Building the Digital Bioprocessing Facility of Tomorrow: AI, Digital Twins and Smart Manufacturing
- AI-driven models enabling predictive process control and real-time optimisation
- Digital twins simulating scale-up scenarios before committing capital expenditure
- Real-time monitoring through connected sensors across the full production line
- Smart, autonomous facilities reducing manual intervention in biologics manufacturing
11:25
Automation and Digital Twin Technologies for Biomanufacturing
- Automation platforms reducing manual intervention across production lines
- Digital twin and simulation tools de-risking scale-up decisions
- Data integration connecting shop-floor systems to enterprise platforms
- Practical starting points for facilities beginning their automation journey
Solution Provider
Reserved for Solution Provider
11:40
Advancing Bioprocessing 4.0: Automation Strategies for Future-Ready Biomanufacturing
- Retrofitting legacy production lines with robotics and automated systems
- Measuring tangible returns from automation investments made during modernisation
- Managing workforce transition and upskilling through digital transformation rollout
- Key lessons learned from a live, in-progress facility upgrade
- Building cybersecurity safeguards into newly connected manufacturing systems
12:05
Data and Analytics: Quick Takes on the Future of Bioprocessing Decisions
- Machine learning accelerating upstream process optimisation and decision-making
- Multivariate data analysis explained for process characterisation teams
- Predictive models catching potential batch failures before they occur
- Soft sensors enabling faster, real-time release testing decisions
02:00
Panel Discussion
IND Readiness: How Much Data Is Enough Before First-in-Human Studies?
- Weighing analytical characterisation depth against the pressure of speed to clinic
- Defining CMC expectations appropriate for early-phase clinical development
- Managing comparability strategies after process or formulation changes occur
- Balancing clinical supply constraints against evolving quality risk management
- Where global regulators are drawing the line today
02:30
Bioinformatics and Computational Biology Accelerating Biologics Discovery
- In-silico modelling accelerating target identification and candidate screening
- Computational tools predicting developability and reducing late-stage failures
- AI-driven sequence and structure analysis speeding biologics design
- Cloud-based platforms enabling faster, more collaborative research
Solution Provider
Reserved for Solution Provider
02:45
Formulating for Complexity: A Conversation on Advanced Therapeutics Medicinal Products
- Key Complexities in CART cell manufacturing
- Leukapheresis , starting material quality and genetic modifications
- Cryopreservation, logistics and Thawing
- Maintaining chain of identity & chain of custody
- Ensuring quality control and release
Dr. Neera Gupta
Vice President, Clinical Development & Medical Affairs, Immuneel Therapeutics Pvt. Ltd., India
03:10
From Discovery to Development: Translational Science Powering Next-Generation Biologics
- AI-enabled target identification accelerating early-stage biologics discovery
- Assessing developability early to guide sound candidate selection strategy
- Platform technologies advancing monoclonal antibodies, CAR-T and gene therapies
- Bridging discovery research with early CMC and manufacturing planning
Melina Soares
Head Innovation, Immuneel Therapeutics Private Limited, India
04:05
Scaling-Up Biologics Manufacturing: Optimizing Process Robustness and Commercial Readiness
- Scale-up considerations spanning upstream and downstream bioprocess stages
- Process intensification strategies without compromising batch-to-batch consistency
- Managing process comparability across manufacturing sites and technology transfers
- Analytical technology flagging deviations before they escalate into failures
- Robust checking required ahead of commercial product launch
04:30
Achieving Successful Technology Transfer: From Process Development to Commercial Manufacturing
- Transfer strategies spanning internal manufacturing sites and CDMO partnerships
- Knowledge management practices supporting a smooth, lower-risk handover
- Defining critical process parameters and critical quality attributes early
- Applying Quality by Design principles to reduce overall transfer risk
- Digital documentation and knowledge transfer minimising delays during handover
Solution Provider
Reserved for Solution Provider
04:45
Driving CMC Excellence: Perspectives Across the Product Lifecycle
- CMC strategies supporting global regulatory filings and approvals
- Lifecycle management practices following process or manufacturing site changes
- Process validation and continued process verification in day-to-day practice
- Navigating post-approval changes amid shifting global regulatory expectations
DAY 2
18 March 2027
08:55
Chairman’s Opening Address
09:00
Visionary Panel
Shaping the Next Era of India's Biologics Industry
- Emerging technologies transforming biologics development pipelines
- Advanced therapeutic platforms reaching commercial scale
- AI and digitalisation reshaping bioprocessing decisions
- Building a stronger domestic innovation ecosystem
- India’s path toward global biologics leadership
09:50
Technologies Powering India’s Biologics Transformation
- Emerging platforms supporting faster, more efficient biologics development
- Digital solutions strengthening data-driven decision-making across the value chain
- Scalable technologies designed for India’s growing manufacturing base
- Global innovation adapted to local regulatory and market needs
Solution Provider
Reserved for Solution Provider
10:05
An Industry Perspective: Where India’s Biologics Sector Is Headed
- Key drivers shaping India's biologics growth trajectory
- Balancing innovation investment with commercial realities
- Building talent and capability to sustain long-term growth
- What the next five years could look like for Indian biologics
Anita Krishnan
Associate Vice President, Biocon Biologics, India
11:00
Breaking the Downstream Bottleneck: Maximising Yield, Recovery & Process Productivity
- Managing downstream pressure from higher upstream titers
- Maximising recovery across purification workflows
- Tackling capacity constraints in downstream operations
- Reducing cycle times and processing bottlenecks
- Balancing productivity with consistent process performance
11:25
Transforming Downstream Operations Through Modern Purification Technologies
- High-capacity chromatography for greater process productivity
- Membrane technologies for faster separation workflows
- Filtration solutions supporting higher product recovery
- Single-use systems for flexible downstream operations
- Integrated platforms reducing processing time and complexity
Solution Provider
Reserved for Solution Provider
11:40
Purifying the Next Generation of Biologics: Downstream Challenges for Bispecifics, Trispecifics & Multispecifics
- Addressing purification challenges created by increasingly complex antibody formats
- Managing aggregates, mispaired species and product-related variants
- Optimising chromatography and filtration strategies for complex molecules
- Balancing purity, recovery and process robustness
- Scaling purification processes from development to commercial manufacturing
12:05
Strengthening Purification Performance: Managing Impurities, Variants & Product Quality in Complex Biologics
- Controlling host-cell proteins and process-related impurities
- Managing aggregates and product-related variants
- Addressing purification challenges for complex biologic formats
- Balancing selectivity, purity and product recovery
- Designing robust purification strategies across diverse pipelines
02:00
Panel Discussion
From Regulatory Approval to Commercial Value: Unlocking Global Opportunities for Indian Biologics
- Moving beyond regulatory approval to successful market adoption
- Scientific differentiation supporting commercial competitiveness
- Regulatory agility across multiple global jurisdictions
- Commercial partnerships accelerating international expansion
- Lifecycle strategies maximising long-term product value
02:30
Strengthening Scientific Evidence Across the Product Lifecycle
- Analytical comparability and biosimilarity assessment under next-generation methods
- Weighing clinical trial data against Real-World Evidence (RWE)
- Risk-based CMC approaches replacing traditional lifecycle management rules
- Pharmacovigilance and post-marketing surveillance demands intensifying after launch
- Data integrity and scientific documentation under growing regulatory scrutiny
Solution Provider
Reserved for Solution Provider
02:45
Commercialising Biologics: Market Access, Pricing & Global Expansion
- GLP-1 and biosimilar patent expiries reshaping India’s pricing landscape
- Market access strategies tailored to new and emerging regions
- Value-based pricing and reimbursement models gaining wider momentum
- Licensing deals and commercial partnerships accelerating market expansion
- Sustaining long-term success through disciplined lifecycle management practices
03:10
Navigating a Shifting Global Regulatory Landscape for Biologics and Biosimilars
- CDSCO’s 2025 revised biosimilar guidelines easing global regulatory convergence
- Reduced reliance on animal studies through stronger analytical characterisation
- Conditional waivers for confirmatory efficacy trials under defined criteria
- Digital submissions and regulatory intelligence tools gaining wider adoption
- Staying inspection-ready across an increasingly connected global marketplace
Pallavi Trivedi
Associate Director, Novo Nordisk, India
04:05
Strategic Outlook Panel
Enabling a Collaborative Biologics Ecosystem for Sustainable Growth and Global Impact
- Cross-sector collaboration driving the next wave of biologics innovation
- CDMO, biotech and pharma partnerships deepening across the ecosystem
- Talent development building the industry’s future leadership pipeline
- Digital culture accelerating innovation and collaboration across teams
04:40
Beyond Biosimilars: Building India’s Next Generation of Innovative Biologics
- Expanding pipelines beyond traditional biosimilar development
- Advancing novel antibodies and emerging biologic modalities
- Strengthening translational capabilities for homegrown biologics innovation
- Converting scientific assets into globally competitive products
2026 SPEAKERS
Vaccine World Summit
Prashant Chawla
Senior General Manager, Manufacturing
Biological E
India
Nupur Sengupta
Senior General Manager
Biological E
India
Amulya Panda
Associate Director & Former Director, NII
Panacea Biotec
India
Navneet Bichha
Senior Program Officer / Global South Fellow
The INCLEN Trust International / CEPI
India
Ankur Mutreja
Director, External Affairs & Health Security
PATH
India
Chigusa Mori
R&D Scientist
JNC Corporation / M R Sanghavi & Co.
India
Swapan K Jana
Director, R&D & Manufacturing
Serum Institute of India
India
Annasaheb Kolpe
Senior General Manager, Vaccines R&D, Virology & Immunology
Biological E
India
Arani Chatterjee
President
Cadila Pharmaceuticals
India
Bhupendra Tripathi
Deputy Director, Infectious Diseases & Vaccine Delivery
Gates Foundation
India
Peter Tygesen
Director, Business Development
SPI Pharma
India
Sudeep Kumar
Chief Operating Officer
Techinvention Lifecare
India
Dennis Christensen
Head, Global Research and Development, Vaccine Adjuvant Systems
Croda
Denmark
Tamal Bhaduri
Deputy General Manager, Research Development
Serum Institute of India
India
Suba Dravida
Founder & Chief Executive Officer
Transcell Biologics
India
Chakshusmathi Ghadiyaram
Head, Pre-Clinical R&D
Mynvax
India
Puneet Kalra
Senior Medical Leader & Therapy Area Lead, Vaccines
Takeda
India
Prem Singh
Director & Senior Technical Advisor, Immunization
Jhpiego
India
Rishabh Jhol
Assistant General Manager
Biological E
India
Sumant Karnik
Advisor & Former Quality Assurance HOD
Haffkine Biopharmaceutical
India
Suresh Beri
Director, Polysaccharide Conjugate Vaccine
Serum Institute of India
India
Biologics Festival India
Dr. Akhilesh Sharma
President and Chief Medical Officer
Alkem Laboratories
India
Maloy Ghosh
Chief Scientific Officer
Zumutor Biologics
India
Yôgananth Râjendran
Vice President, Global Regulatory Affairs
Kashiv Biosciences
India
Sanjeev Gupta
Sr. Vice President - Advanced Biotech Lab
Ipca Laboratories
India
Dr. Suyamburam Sathasivam
Head of External Manufacturing and Global Supply Operations; Head of Clinical Supply
SUN Pharmaceuticals
India
Anupam Chhabra
Executive Director
Cartogene Therapeutics
India
Manda Venkata Sasidhar
Chief Scientific Officer / Founder
Urvogelbio / Apollo Hospital Educational and Research Foundation
India
Dr. Vaibhav Salvi
Director and Head – Clinical Study Unit, India and South East Asia
Sanofi
India
Hemasunder Reddy
Director, APAC
Pfanstiehl
Singapore
Bhupal Reddy Auothu
Site Head – CAR-T Manufacturing & Operations
Dr. Reddy’s Laboratories
India
Priyankar Sen
Associate Professor, Centre for Bio-Separation Technology (CBST)
Vellore Institute of Technology
India
Dr. Shubhadeep Sinha
Senior Vice President, Clinical Development and Medical Affairs
Hetero
India
Dr. Nitu Sinha
Vice President & Head Pharmacovigilance
Mankind Pharma
India
Kinnari Vyas
Associate Vice President QA
Kashiv Biosciences
India
Tulip Nuwal
Vice President and Head CGT
Intas Pharmaceuticals
India
Pallavi Trivedi
Associate Director
Novo Nordisk
India
Saiful Fazulul Haq
Asia Pacific Technical Support Manager
Procelys by Lesaffre
Singapore
Dr. Pawan Kumar Gupta
President
Stempeutics
India
Dr. Ankur Mutreja
Director – External Affairs & Global Health Security
PATH
India
Dr. Santosh Taur
Director Medical Affairs, Vaccines & Digital
Pfizer Ltd.
India
Dr. Tathagata Dutta
President
JODA S EXPOIM PVT LTD.
India
Dr. Mradul Tiwari
Senior Manager, Upstream Processing, Department of Biotechnology
Sun Pharmaceutical Industries Ltd.
India
Rakesh Kumar Sinha
Senior Vice President & Head-Drug Product Manufacturing
Biological E. Limited
India
Nithin Choudhary
Head Quality – CAR T
Dr. Reddy's Laboratories Ltd.
India
Dr. Vaibhav Salvi
Director and Head – Clinical Study Unit, India and South East Asia
Sanofi
India
Dr. Prem Singh
Director & Senior Technical Advisor, Immunization
Jhpiego
India
Dr. Akhilesh Sharma
President & Chief Medical Officer
Alkem Laboratories
India
Pallavi Trivedi
Associate Director
Novo Nordisk
India
Dr. Chakshusmathi Ghadiyaram
Head – Pre-Clinical R&D
Mynvax
India
Dr. Mandeep Singh Dhingra
Director and Head, R&D Programs
CEPI
USA
Dr. Rajni Kant
Sr Adviser, VHAI, Visiting Professor, SEARCH, Former Director, ICMR-RMRC, Gorakhpur, Chair-Disease Elimination & Scientist G & Head, Policy & Communications
ICMR Hqrs.
India
Dr. Kapil Maithal
President – Vaccines & Diagnostics
Zydus Lifesciences Limited
India
Contact
GOLD
SILVER
EXHIBITION & NETWORKING
Attendance from
Developing Countries
70%
Attendance from
Decision Makers
85%
By Geography
Educate the market about what you offer.
Position yourselves as leaders in your field along side key industry figure
Raise brand awareness
Enjoy the option of privately arranged meetings and consultations with selected potential clients.
Hold face to face meetings with your target profile
OUR PAST PARTNERS
Radisson Blu Hotel, London Heathrow
140 Bath Road, Harlington, Hayes UB3 5AW, UK
Travel Options
By London Underground
From Heathrow Airport
Taxi or Ride-Hailing
By Car
From Other UK Cities
Accommodation Options
Explore recommended hotels near the venue.
Venue Hotel
Radisson Blu Hotel, London Heathrow
140 Bath Road, Hayes, Middlesex, UB3 5AW
venue for this event
To book a room at this hotel, please click the button below
London Heathrow Mariott Hotel
Bath Road Heathrow, Airport, Hayes UB3 5AN
4 minute walk from venue
To book a room at this hotel, please click the button below
Ibis Style London Heathrow Airport
272 Bath Rd, London UB3 5AY
8 minute walk from venue
To book a room at this hotel, please click the button below
Premier Inn London Heathrow
15 Bath Rd, London TW6 2AB
5 minute drive from venue
To book a room at this hotel, please click the button below
Please find the booth allocation in the table below.
4
Alfa Laval
11
QuickSTAT
12
BSP Pharmaceuticals
14
AsTec Chemicals
17
Unchained Labs
19
Inprocess LSP
18
Kemwell Biopharma
